vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and TPG Mortgage Investment Trust, Inc. (MITT). Click either name above to swap in a different company.
TPG Mortgage Investment Trust, Inc. is the larger business by last-quarter revenue ($20.4M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs -0.8%, a 65.8% gap on every dollar of revenue. On growth, TPG Mortgage Investment Trust, Inc. posted the faster year-over-year revenue change (17.7% vs -25.7%). Over the past eight quarters, TPG Mortgage Investment Trust, Inc.'s revenue compounded faster (9.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
CTMX vs MITT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $20.4M |
| Net Profit | $-154.0K | $13.3M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 67.1% |
| Net Margin | -0.8% | 65.0% |
| Revenue YoY | -25.7% | 17.7% |
| Net Profit YoY | 97.6% | -7.0% |
| EPS (diluted) | — | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | $18.7M | $17.8M | ||
| Q1 25 | $50.9M | $18.8M | ||
| Q4 24 | $38.1M | $17.4M | ||
| Q3 24 | $33.4M | $14.9M | ||
| Q2 24 | $25.1M | $16.4M | ||
| Q1 24 | $41.5M | $17.2M |
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $-154.0K | $3.9M | ||
| Q1 25 | $23.5M | $11.5M | ||
| Q4 24 | $18.9M | $14.3M | ||
| Q3 24 | $5.7M | $16.6M | ||
| Q2 24 | $-6.5M | $3.9M | ||
| Q1 24 | $13.8M | $20.9M |
| Q4 25 | — | 67.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | 20.9% | ||
| Q1 25 | 44.4% | 54.6% | ||
| Q4 24 | 46.4% | 76.7% | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | 18.4% | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 65.0% | ||
| Q3 25 | — | 102.5% | ||
| Q2 25 | -0.8% | 22.2% | ||
| Q1 25 | 46.2% | 60.9% | ||
| Q4 24 | 49.6% | 82.2% | ||
| Q3 24 | 17.2% | 111.3% | ||
| Q2 24 | -26.0% | 24.0% | ||
| Q1 24 | 33.3% | 121.6% |
| Q4 25 | — | $0.27 | ||
| Q3 25 | — | $0.47 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $0.21 | ||
| Q4 24 | — | $0.30 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $57.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $560.7M |
| Total Assets | $175.1M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $57.8M | ||
| Q3 25 | — | $59.0M | ||
| Q2 25 | $49.0M | $88.7M | ||
| Q1 25 | $47.6M | $115.5M | ||
| Q4 24 | $38.1M | $118.7M | ||
| Q3 24 | $40.6M | $102.5M | ||
| Q2 24 | $43.2M | $120.9M | ||
| Q1 24 | $36.2M | $100.3M |
| Q4 25 | — | $560.7M | ||
| Q3 25 | — | $559.8M | ||
| Q2 25 | $119.9M | $536.4M | ||
| Q1 25 | $25.0M | $543.9M | ||
| Q4 24 | $-456.0K | $543.4M | ||
| Q3 24 | $-23.5M | $540.1M | ||
| Q2 24 | $-31.2M | $533.5M | ||
| Q1 24 | $-31.7M | $539.6M |
| Q4 25 | — | $8.7B | ||
| Q3 25 | — | $9.0B | ||
| Q2 25 | $175.1M | $7.5B | ||
| Q1 25 | $98.5M | $7.3B | ||
| Q4 24 | $120.5M | $6.9B | ||
| Q3 24 | $139.0M | $7.0B | ||
| Q2 24 | $159.2M | $7.1B | ||
| Q1 24 | $184.7M | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $59.6M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 4.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $59.6M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | $-15.8M | $11.5M | ||
| Q1 25 | $-21.0M | $12.0M | ||
| Q4 24 | $-19.9M | $55.8M | ||
| Q3 24 | $-20.7M | $14.5M | ||
| Q2 24 | $-19.5M | $13.7M | ||
| Q1 24 | $-26.0M | $12.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 4.48× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 2.92× | ||
| Q1 25 | -0.89× | 1.05× | ||
| Q4 24 | -1.05× | 3.91× | ||
| Q3 24 | -3.61× | 0.87× | ||
| Q2 24 | — | 3.50× | ||
| Q1 24 | -1.89× | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MITT
Segment breakdown not available.
